Cyprotex sniffs out drug candidates that could cause ill effects. The firm produces systems that monitor and evaluate drug discovery experiments. Cyprotex is a contract research organization (CRO) that aids pharmaceutical and biotechnology companies with discovery services based around the ADME properties (absorption, distribution, metabolism, and elimination) of a potential drug. Its top products include cyprotox in vitro toxicity tests for early stage candidates and ADME and pharmacokinetics (the study of the ADME process) tests and prediction systems for late-stage candidates. Cyprotex offers services around the globe and has locations in the UK and the US. Evotec acquired Cyprotex for £55.7 million in late 2016.